Sucralfate

Both products have short-term active duodenal-ulcer treatment labeling, up to eight weeks. Tablets also have maintenance treatment after healing at a reduced dose. The suspension label does not establish that maintenance regimen or equivalence to tablets.

This profile does not supply an H. pylori eradication, gastric-ulcer, reflux, stress-ulcer prevention or compounded/tube regimen. Sucralfate treats the ulcer surface; it does not by itself establish elimination of an underlying cause or prevention of recurrence.

Shake suspension well before measuring. The selected concentration is 1 g / 10 mL. Antacids may be used for pain as prescribed, but not within thirty minutes before or after sucralfate. Resolve other medicines’ timing individually; the studied two-hour-before result is not an instruction for every drug.

Pediatric safety and effectiveness are unestablished. No numeric renal or hepatic adjustment schedule is supplied; renal aluminum risk can make simple dose extrapolation unsafe. Elderly dose selection should be cautious. No independently verified missed-dose, crushing or enteral-tube protocol is supplied.

Known hypersensitivity to sucralfate or product ingredients is contraindicated. Renal failure is a labeled caution requiring careful selection, rather than an invented universal creatinine-clearance contraindication.

Neither selected Carafate label has a boxed warning. The absence of a box does not reduce the seriousness of inappropriate injection, allergy or renal aluminum toxicity.

Constipation is the most frequent reported trial complaint. Other reported effects include nausea, diarrhea, vomiting, dyspepsia, dry mouth, dizziness, headache and rash. Postmarketing reports include airway/facial swelling, bronchospasm and anaphylactic reactions; formulation attribution is not always known. Bezoars and aspiration are clinically important complications.

Reported affected medicines include digoxin, fluoroquinolones, levothyroxine, phenytoin, tetracyclines, ketoconazole, quinidine, theophylline and selected H2 blockers. These are label examples, including legacy products; not all require identical spacing. Administering selected studied medicines two hours before sucralfate eliminated those studied interactions, but this was not demonstrated universally.

Subtherapeutic prothrombin-time case reports with warfarin contrast with two studies showing no effect; monitor anticoagulation where clinically appropriate without predicting a guaranteed INR direction. Aluminum-containing antacids add to renal aluminum burden; preserve the separate thirty-minute antacid administration restriction.

There are no adequate controlled pregnancy studies; animal findings do not establish human safety. Use in pregnancy only when clearly needed under clinical review. Excretion in human milk is unknown and the labels advise caution during breastfeeding.

Safety and effectiveness in pediatric patients have not been established. Older-adult clinical information is limited; consider concurrent diseases, medicines and reduced renal function when selecting treatment and monitoring.

Use cautiously in chronic renal failure or dialysis because absorbed aluminum cannot be adequately cleared. Protein-bound aluminum does not cross dialysis membranes; dialysis is not a reason to dismiss accumulation. The labels provide no numeric hepatic adjustment or validated renal dose table.

An ulcer-adherent complex with proteinaceous exudate provides a barrier to acid, pepsin and bile salts. The exact healing mechanism is not fully defined; the effect is predominantly local.

Gastrointestinal absorption is minimal. Absorbed sulfated disaccharide is principally excreted in urine; some aluminum is absorbed, explaining renal toxicity concerns. The suspension label specifically states that clinical equivalence to tablets has not been demonstrated.

Review ulcer response and the planned course, constipation, swallowing ability, renal function and aluminum exposures. In diabetes using suspension, monitor glucose. Review the whole medicine schedule with a pharmacist, especially thyroid replacement, seizure medicines, antibiotics or anticoagulation. Shake and measure suspension accurately; never inject.

Seek medical or Poison Control advice for excessive dosing or concerning symptoms. Human overdose experience is limited and the labels provide no specific treatment recommendation; animal tolerance is not a safe human threshold. Report severe abdominal symptoms, airway swelling or breathing difficulty urgently.

Tablet

AbbVie Carafate 1 g

Tablet appearance

Light pink, scored, oblong; CARAFATE / 1712

Tablet package

Bottle 100 · NDC 58914-171-10

Suspension

Pink 1 g / 10 mL; bottle 420 mL · NDC 58914-170-14

Selected tablets contain 1 g sucralfate; selected oral suspension contains 1 g per 10 mL. Check all inactive ingredients for allergy. No compounded concentration, opened-tablet stability or enteral-tube recipe is verified here.

Tablets: controlled room temperature 15–30°C. Suspension: 20–25°C; avoid freezing and shake well before use. Follow the actual dispensed container and expiry; do not infer a universal post-opening or compounded beyond-use date.